1. Work trial presentation
July â September 2022
Presented by
Pitakthai Chamtim, Ph.D.
Researcher of Academic service unit, GLP testing facility
National Laboratory Animal Center (NLAC), Thailand
October 2022
1
2. Personal information
Name: Pitakthai Chamtim Age : 31
Position: Researcher (custodian), Academic service unit, GLP testing facility
Address: National Laboratory Animal Center, Mahidol university, Thailand
Contact: +66 2441 9342 Ext. 149 E-mail: pitakthai.cha@mahidol.ac.th
Education Major Institute Year
Bachelor of Science (B.S.) Department of Biology,
Faculty of Science
Naresuan university 2010-2013
Master of Science (M.S.) Department of Zoology,
Faculty of Science
Kasetsart university 2014-2016
Philosophy of doctor (Ph.D.) Department of Biochemistry,
Faculty of Science
Kasetsart university 2017-2022
2
Working experience: Assistance researcher at Institute of Nutrition,
Mahidol University
3. 3
Training plan for custodian (3 months)
Test guidelines
âĒ Introduction OECD Principles of GLP series No. 1
âĒ Standard operating procedure (SOP) and form (custodian)
âĒ ISO 10993 Biological evaluation of medical device
â Part 12: Sample preparation and reference materials
â Part 18: Chemical characterization of medical device materials within a risk management
process
â Part 19: Physico-chemical, morphological and topographical characterization of materials
On study (Mini room) and custodian/preparation (custodian room)
âĒ Non-GLP2022-14 (Wound dressing with PVA/CMC with HA)
âĒ GLP-2022-21 (Subchronic toxicity of Centella asiatica)
4. Non-GLP2022-14 (Wound dressing with PVA/CMC with HA)
4
Title Efficiency evaluation of wound dressing made from Polyvinyl alcohol and carboxymethyl
cellulose (PVA/CMC) loaded Chlorhexidine gluconate combined with Hyaluronic acid
Statement This study aimed to evaluate the efficiency of wound healing of wound dressing made
from PVA/CMC loaded Chlorhexidine gluconate combined with Hyaluronic acid in Wistar Rat.
Experimental Starting Date 03/08/22
Experimental Completion Date 16/08/22
Responsibility The management of test items includes receiving, storage, and preparation. In experiment, Wistar
Rats of test group 1 and test group 2 were applied with wound dressing made from PVA/CMC
loaded chlorhexidine gluconate combined with Hyaluronic acid (HA) and non Hyaluronic acid ,
respectively. Every day after administration day to day 7th, the wound dressing will be removed and
then the new wound dressing will be applied. After day 7th animals will be sacrificed.
5. GLP2022-21 (Sub-chronic Oral Toxicity Testing of Centell-S in Wistar Rats)
5
Title Sub-chronic Oral Toxicity Testing of Centell-S in Wistar Rats
Statement In this study, Centell-S were orally administered daily to several groups of experimental
animals for period of at least 90 days. The study provided information on the major
toxic effects, indicated target organs and the possibility of accumulation of test item.
Experimental Starting Date 20/07/22
Experimental Completion Date 31/10/22 to 31/05/23
Responsibility I prepared the sterile water for mixing with test items and administration to 6 groups of
experimental animal for period of at least 90 days.
6. Non-GLP2022-22 (Skin sensitization test)
6
Title Skin sensitization test of Cellulose hydrogel wound dressing patch in Dunkin Hartley Guinea Pig
Statement This study aimed to assess possible contact hazards from chemicals released from medical wound
dressing patch which may produce skin sensitization.
Experimental Starting Date 11/07/22
Experimental Completion Date 24/08/22
Responsibility The management of test items includes receiving, storage, and preparation. Induction phase, I
observed the administer the test sample using the topical application to the clipped upper back
region of each animal using appropriate patches of the test sample. The frequency of dosing in
induction phase: three days per week of three weeks.
7. 7
Introduction OECD Principles of GLP series No. 1
Organization for Economic Co-operative and Development (OECD) Principles of GLP series No. 1
ï The mission of the Organisation for Economic Co-operation and Development (OECD) is to
promote policies that will improve the economic and social well-being of people around
the world (34 Member countries).
ï Good Laboratory Practice (GLP) is a quality system concerned with the organizational
process and the conditions under which non-clinical health and environmental safety
studies are planned, performed, monitored, recorded, archived and report.
8. 8
Introduction OECD Principles of GLP series No. 1
Organization for Economic Co-operative and Development (OECD) Principles of GLP series No. 1
9. 9
Introduction OECD Principles of GLP series No. 1
Organization for Economic Co-operative and Development (OECD) Principles of GLP series No. 1
ï Apparatus, Material, and Reagents
ï Apparatus, including validated computerized systems, used for the generation, storage and retrieval of data, and for controlling
environmental factors relevant to the study should be suitably located and of appropriate design and adequate capacity.
ï Apparatus used in a study should be periodic inspected, cleaned, maintained, and calibrated according to Standard Operating
Procedures. Records of these activities should be maintained. Calibration should, where appropriate, be traceable to national or
international standards of measurement.
ï Apparatus and materials used in a study should not interfere adversely with the test systems.
ï Chemicals, reagents, and solutions should be labelled to indicate identity (with concentration if appropriate), expiry date and
specific storage instructions. Information concerning source, preparation date and stability should be available. The expiry date
may be extended on the basis of documented evaluation or analysis
10. 10
Introduction OECD Principles of GLP series No. 1
Organization for Economic Co-operative and Development (OECD) Principles of GLP series No. 1
ï Test system
ï Physical/Chemical
ï Apparatus used for the generation of physical/chemical data should be suitably located and of appropriate design
and adequate capacity.
ï The integrity of the physical/chemical test systems should be ensured.
ï Test and reference items
ï Receipt, Handling, Sampling and Storage
ï Records including test item and reference item characterization, date of receipt, expiry date, quantities received and
used in studies should be maintained.
ï Handling, sampling, and storage procedures should be identified in order that the homogeneity and stability are
assured to the degree possible and contamination or mix up are precluded.
11. 11
Introduction OECD Principles of GLP series No. 1
Organization for Economic Co-operative and Development (OECD) Principles of GLP series No. 1
ï Test and reference items
ï Receipt, Handling, Sampling and Storage
ï Storage container(s) should carry identification information, expiry date, and specific storage instructions.
ï Characterization
ï Each test and reference item should be appropriately identified (e.g., code, Chemical Abstracts Service Registry
Number [CAS number], name, biological parameters.
ï For each study, the identity, including batch number, purity, composition, concentrations, or other characteristics to
appropriately define each batch of the test or reference items should be known.
ï In cases where the test item is supplied by the sponsor, there should be a mechanism, developed in co-operation
between the sponsor and the test facility, to verify the identity of the test item subject to the study.
12. 12
Introduction OECD Principles of GLP series No. 1
Organization for Economic Co-operative and Development (OECD) Principles of GLP series No. 1
ï Test and reference items
ï Characterization
ï The stability of test and reference items under storage and test conditions should be known for all studies.
ï If the test item is administered or applied in a vehicle, the homogeneity, concentration and stability of the test item
in that vehicle should be determined. For test items used in field studies (e.g., tank mixes), these may be determined
through separate laboratory experiments.
ï A sample for analytical purposes from each batch of test item should be retained for all studies except short-term
studies.
13. 13
Introduction OECD Principles of GLP series No. 1
Organization for Economic Co-operative and Development (OECD) Principles of GLP series No. 1
ï Standard Operating Procedures
ï The stability of test and reference items under storage and test conditions should be known for all studies.
ï If the test item is administered or applied in a vehicle, the homogeneity, concentration and stability of the test item
in that vehicle should be determined. For test items used in field studies (e.g., tank mixes), these may be determined
through separate laboratory experiments.
ï A sample for analytical purposes from each batch of test item should be retained for all studies except short-term
studies.
17. Solvents for
medical device extraction
Mr. Pitakthai Chamtim
Researcher, National laboratory animal center (NLAC)
18. Extractables and leachables testing
âĒ Differences between Extractables and Leachables
â Extractables: compounds extracted from contacted materials of
pharmaceuticals under severe conditions (solvent,
temperature, pH etc.).
â Leachables: compounds that migrate into the final formulations
from contact materials of pharmaceuticals under actual process
conditions (Manufacturing, Packaging, Storage, Distribution,
Administration).
Ref: Extractables & LeachablesïžE&Lïž - Eurofins Scientific
19. Extractables and leachables (E & L) testing
âĒ Leachables from medical devices can enter the body by 2 routes
â Leachables from medical devices to enter a drug product that carries the leachable into a patient
âĒ Infusion pump (āđāļāļĢāļ·āđāļāļāļāļ§āļāļāļļāļĄāļāļēāļĢāđāļŦ āđāļŠāļēāļĢāļĨāļ°āļĨāļēāļĒāļāļēāļāļŦāļĨāļāļāđāļĨāļ·āļāļāļāļē), syringe, syringe filter
â Leachables from medical devices directly migrate into a patient from direct tissue contact
âĒ Dental implant, artificial joint, stents, bandages, contact lens
Ref: Extractables & LeachablesïžE&Lïž - Eurofins Scientific
20. Solvents for medical device extraction
âĒ A solvent is a substance that dissolves a solute resulting in a solution. Solvents can be classified into two
categories: polar and non-polar.
â Polar solvents are solvents with large dipole moments, where part of the molecule has a partial
positive charge and part has a partial negative charge.
â Nonpolar solvents have low or sometimes, no dipole moment at all. Nonpolar molecules form either
when electrons are equally shared between atoms in a molecule or when the arrangement of
electrons in a molecule is symmetry.
Ref: https://sciencenotes.org/polar-and-nonpolar-molecules/
21. Polar solvents and Nonpolar solvents
Ref: Polar vs. Nonpolar Solvents: Identifications and Examples - PSIBERG /
âĒ Polar solvents: Water (H2O), Acetone (C3H6O), Acetonitrile (C2H3N), N,N-Dimethylformamide (DMF, C3H7NO),
Dimelthylsulfoxide (DMSO, C2H6OS), Isopropanol (C3H8O), Methanol (CH3OH) etc.
âĒ Nonpolar solvents: Alkanes (pentane, hexane, heptane), Aromatics (benzene, toluene, xylene), Diethyl ether
[(C2H5)2O], Tetrahydrofuran (THF), Pyrrole (C4H5N), Ethyl acetate (C4H8O 2), 1,4-Dioxane (C4H8O2 ), Pyridine
(C5H5N), Chloroform (CHCl3), Carbon tetrachloride (CCl4 ), Acetic acid [CH3COOH (exits in the form of dimers
and behaves as a nonpolar solvent)]
22. â Polar protic solvents contain at least one hydrogen atom connected directly to
an electronegative atom (such as F, N, O) and thus, can make hydrogen bonds.
Generally, any solvent with a labile H+ is the protic solvent.
â Polar aprotic solvents do not contain any hydrogen atom connected directly to
highly electronegative atoms and so are not capable of forming hydrogen bonds.
Aprotic solvents lack acidic protons. Thus, they cannot act as proton donors in
hydrogen bonding.
Polar solvents: Protic and Aprotic
Ref: Protic vs Aprotic Solvents (with Examples) - PSIBERG/
23. Polar solvents: Protic and Aprotic
Ref: Protic vs Aprotic Solvents (with Examples) - PSIBERG/
24. Solvents for medical device extraction: Sterile
water
â Sterile water is polar protic solvents and good solvents for polar and charged species.
âĒ Polar molecules readily dissolve in water because the positive part of the polar molecule is
attracted to the oxygen atom, while the negative part is attracted to the hydrogen atom.
â It is used as a solvent for inorganic compounds as well as salts of organic acids and bases.
â It is a great solvent because it is amphoteric which can act as both an acid and a base.
Amphoterism makes water a better solvent than most other polar molecules.
â Water dissolves polar molecules, including salts, sugars, many gases, proteins, simple
alcohols, and DNA. But, it isnât a universal solvent because it canât dissolve hydrophobic
or nonpolar molecules, such as fats, oils, some hydroxides, and most metal oxides,
silicates, and sulfides.
Ref: Why Is Water Called the Universal Solvent? (sciencenotes.org)
25. Vehicles for preclinical
oral toxicity test
Mr. Pitakthai Chamtim
Researcher, National laboratory animal center (NLAC)
26. Vehicles for preclinical oral toxicity test
â Formulation vehicles includes a vehicle, excipients and a container/container components. A vehicle
can be aqueous or non-aqueous.
âĒ Aqueous vehicles: Sterile water, Purified water, polyethylene glycol (liquid)
âĒ Non aqueous vehicles: Vegetable oils (corn oil or sesame oil), Glycerin, Polyethylene glycol (PEG), Propylene
glycol, Alcohol, Other agents (ethyl oleate, isopropyl myristate)
â Injections are prepared by dissolving, solubilising or suspending the active ingredient in a suitable
vehicle.
â The ideal properties of the vehicle include pharmacologically inert, non-toxic, physically and
chemically inert and does not interfere with therapeutic effect of the active pharmaceutical
ingredient (API) .
Ref: Formulation Vehicles - Grade: 1.1 - Formulation Vehicles The formulation includes a vehicle, - StuDocu
27. Vehicles for preclinical oral toxicity test
â Formulation vehicles includes a vehicle, excipients and a container/container components.
Ref: ACS Webinars ÂŪ at acswebinars@acs.or
28. Vehicles for preclinical oral toxicity test
â 1. Nonirritating
â 2. Non toxic
â 3. Non-sensitizing
â 4. Must no exert pharmacological activity
â 5. It must not affect the activity of medicinal agents
â 6. Physically and chemically stable at various pH levels.
â 7. Its viscosity must be such as to allow ease of injection (syringeability)
â 8. Its fluidity must be maintained over a wide temperature
â 9. Its boiling point must be sufficiently enough to permit heat sterilization
Ref: Parenteral Medications and Sterile Fluids Injections are sterile (slidetodoc.com)
29. Vehicles for preclinical oral toxicity test: Purified
water
â There are three main types of vehicles, water for injection, non-aqueous water miscible and non-
aqueous non-water miscible
â Purified water:
âĒ Purified by distillation or by reverse osmosis
âĒ May not contain added substances
âĒ Although water for injection is not required to be sterile, it must be pyrogen free
âĒ It is intended to be used in the manufacture of injectable products which are to be sterilized after
preparation.
âĒ It should be stored in tight containers
âĒ It should be used within 24 hours following its collection
Ref: Parenteral Medications and Sterile Fluids Injections are sterile (slidetodoc.com)
āļĨāļ°āļĨāļēāļĒāđāļ āđāļāļąāļāļāđāļē
āđāļĨāļ°āļŠāļēāļĢāļāļĩāđāđāļĄāđāđāļāđ
aqueous
30. Vehicles for preclinical oral toxicity test: Sterile
water
â There are three main types of vehicles, water for injection, non-aqueous water miscible and non-
aqueous non-water miscible
â Sterile water
âĒ It has been sterilized and packaged in single dose containers
âĒ It must be pyrogen free and may not contain an antimicrobial agents or other added substance
âĒ This water is intended to be used as a solvent, vehicle or diluent for already sterilized and
packaged injectable medications.
Ref: Parenteral Medications and Sterile Fluids Injections are sterile (slidetodoc.com)
āđāļāđāļĢāđāļāļ āļāļ·āļ āļŠāļēāļĢāļāļĩāđāļāđāļāđāļŦāđāđāļāļīāļāļāļēāļāļēāļĢāđāļāđāļāļēāļāļĒāļē
āļāļĩāļāļāļķāđāļāļĄāļąāļāļāļāđāļāļāđāļēāļāļĩāđāđāļ āđāļĨāļ°āļĨāļēāļĒāļāļąāļ§āļĒāļē āđāļāđāļĢāđāļāļāļāļĩāđ
āđ āļāđ āļ āļāļīāđāļ āļŠāđ āļ§ āļ āļ āļ āļ āļ āļāļą āļ āđ āļ āļĨ āļĨāđāđ āļ āļ āļāļĩ āđ āļĢāļĩ āļĒ
(endotoxin pyrogen)āđāļāđāļāļāļāļĩāđāļĢāļĩāļĒāđāļāļĢāļĄāļāļ§āļ
āđāļĨāļ°āđāļāđāļāļĢāļĄāļĨāļāļāļķāđāļāđāļāđāļāļĢāļĄāļĨāļāļāļēāđāļŦ āđāđāļāļīāļāļāļ§āļēāļĄ
āļĢāļļāļāđāļĢāļāļāļāļāļāļēāļĢāļāđāļāđāļ āđāļŠāļđāļāļāļ§āđāļēāļāļķāđāļāļĨāļ°āļĨāļēāļĒāļāđāļēāđāļ āđāļāļĩāđāļ
āļāđāļēāļāļĩāđāđāļ āđāđāļāļĢāļĩāļĒāļĄāļĒāļēāļāļĩāļ āļāļķāļāļ āđāļāļāļĄāļĩāļāļēāļĢāļāļāļŠāļāļāļŦāļēāđāļ
āđāļĢāđāļāļ
31. Purified water and Sterile water
Ref: https://www.honeymangroup.com/laboratories/water-testing/wfi/, https://aqua-chem.com/difference_purified_water_pw_water_for_injection_wfi/
32. Vehicles for preclinical oral toxicity test: Sterile
water
Table of Index of Vehicles and ExcipientsâCodex and Details.
Abbreviations: BHA, butylated hydroxyanisole; BHT, butylated hydroxytoluene; CAS, Chemical Abstracts Service; CMC, carboxymethylcellulose; DAM, diacetylmonoxime; DMA, dimethyl
acetamide; DMSO, dimethylsulfoxide; EDTA, ethylenediaminetetraacetic acid; EP, European Pharmacopeia; HPMC, hydroxypropyl methylcellulose; IA, intra-articular; IM, intramuscular; IP,
intraperitoneal; IV, intravenous; NF, National Formulary; NMP, N-Methyl-2-pyrrolidone; PBS, phosphate-buffered saline; PEG, polyethylene glycol; PET, polyethylene terephthalate; PO, oral; PVP
VA, polyvinylpyrrolidone/vinyl acetate; RAMEB, Randomly methylated b-cyclodextrin; SC, subcutaneous; TPGS, D-a-tocopheryl polyethylene glycol succinate; USP, United States Pharmacopeia.
Ref: Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility (sagepub.com)
33. Vehicles for preclinical oral toxicity test: Sterile
water
Ref: Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility (sagepub.com)
āđāļ āļŠāļąāļāļāļēāļĢāļąāļāļāļāļāļŠāļŦāļĢāļąāļāļāđāļĄāļĢāļīāļāļē (United States
Pharmacopeia āļŦāļĢāļ·āļāļĒāđāļāļ§āđāļē USP) āļāļ·āļāļāļāļāđāļāļĢāļāđāļēāļ
āļ§āļīāļāļĒāļēāļĻāļēāļŠāļāļĢ āđāļāļĩāđāđāļĄāđāđāļāđāļŦāļāđāļ§āļĒāļāļēāļāļĢāļąāļ āļĄāļĩāļŦāļāđāļēāļāļĩāđāļāļēāļŦāļāļ
āļĄāļēāļāļĢāļāļēāļāļŠāļēāļāļēāļĢāļāļ°āļŠāļēāļŦāļĢāļąāļāļĒāļēāđāļĨāļ°āļāļĨāļīāļāļ āļąāļāļāđāļĒāļēāđāļ
āļŠāļŦāļĢāļąāļāļāđāļĄāļĢāļīāļāļēāļāļĒāđāļēāļāđāļāđ āļāļāļēāļāļāļēāļĢ
34. Vehicles for preclinical oral toxicity test: Sterile
water
Ref: Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility (sagepub.com)
35. Vehicles for preclinical oral toxicity test: Sterile
water
Ref: Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility (sagepub.com)
36. Vehicles for preclinical oral toxicity test: Oils
â There are three main types of vehicles, water for injection,
non-aqueous water miscible and non-aqueous non-water
miscible
â Non-aqueous non-water miscible vehicles include fix oils as
an important group.
â Fixed oils must be of vegetable origin so that they will be
metabolized
â Examples include corn oil, sesame oil, cotton seed oil.
â liquid at room temperature and not become rancid readily
â They should be odorless. They mustnât contain mineral oils or
solid paraffins as they will not be metabolized and leads to
adverse reactions.
Ref: Formulation Vehicles - Grade: 1.1 - Formulation Vehicles The formulation includes a vehicle, - StuDocu
37. Vehicles for preclinical oral toxicity test: Ethyl
oleate
â Ethyl oleate, a synthetic ester, can also be used as a vehicle. It is mandatory to state vehicle
composition on the label due to risk of allergic reactions.
âĒ Advantages include enhancement of drug stability and prolong or âdepotâ effect
âĒ they can only be administered SC or IM, may cause tissue necrosis and thus pain
âĒ risk of solidifying at room temperature and contamination of syringe and needle makes them difficult to clean
Ref: Formulation Vehicles - Grade: 1.1 - Formulation Vehicles The formulation includes a vehicle, - StuDocu
āļāļēāđāļāđ āļāļ āđāļāļāļĢāļ°āļāļļāļāļāļāđāļāļĢāļ°āļāļāļāļāļāļ
Vehicle āļāļĩāđāļāļāļāļĨāļēāļ āđāļāļ·āđāļāļāļāļēāļ
āđāļŠāļĩāđāļĒāļāļāđāļāļāļēāļĢāđāļāļīāļāļāļēāļāļēāļĢāđāļāđ
38. Vehicles for preclinical oral toxicity test: Corn oil
â Corn oil is well tolerated in short-term studies ( âĪ1 month), but which causes altered body
weight gain, survival and tumor incidence when administered chronically in rats [7].
NOAEL (no-observed-adverse-effect level) āļŦāļĄāļēāļĒāļāļķāļ āļāļĢāļīāļĄāļēāļāļāļāļ
āļŠāļēāļĢāđāļāļĄāļĩāļāļĩāđāļĄāļēāļāļāļĩāđāļŠāļļāļ āļāļķāđāļāđāļāđāļĢāļąāļāļāļļāļāļ§āļąāļāđāļĨāđāļ§āđāļĄāđāļāļēāđāļŦāđāđāļāļīāļāļāļ§āļēāļĄāđāļāđ āļāļāļīāļĐāļŦāļĢāļ·āļ
āļāļĨāđāļŠāļĩāļĒ (adverse effects) āđāļāđ āļāđāļāļĢāđāļēāļāļāļēāļĒ
44. Vehicles for preclinical oral toxicity test: 1% CMC
â Carboxymethylcellulose (CMC, carmelose) is the suspending/emulsifying agents.
â The agents in this class are the cellulose derivatives - specifically methylcellulose (MC),
carboxymethylcellulose (CMC, carmelose) and hydroxypropylmethylcellulose (HPMC).
Ref: Expert Opin. Drug Metab. Toxicol. (2013) 9(12)
Carboxymethylcellulose (CMC, carmelose) hydroxypropylmethylcellulose (HPMC).
âĒ These vehicles offer the advantages of low toxicity, poor bioavailability and the ability to create uniform
suspensions or emulsions in relatively low percentage formulations.
48. Vehicles for preclinical oral toxicity test: 1% CMC
Ref: Gad et al, International Journal of Toxicology 2016, Vol. 35(2) 95-178
âĒ After preparing a formulation best suited for its intended purpose, it is also necessary to characterize it for
drug content, assay, and other relevant technique that would give first-hand information on its physical
and chemical stability.
âĒ Depending on the type of formulation being characterized, its testing parameter will change as they are
varied in the type of excipient used, method of preparation, and its use. For a detailed list of the
characterization parameters for the formulations or delivery systems mentioned, please refer to Table III.
*Drug uniformity (āļāļ§āļēāļĄāļŠāļĄāđāļēāđāļŠāļĄāļāļāļāļāļāļąāļ§āļĒāļē)
*Ease of redispersion (āļāļēāļĢāļāļēāđāļŦ āđāđāļāļīāļāļāļēāļĢāļāļĢāļ°āļāļēāļĒāļāļāļāļĒāļē)
55. Biological evaluation of medical devices (ISO-10993)
Part 12: Sample preparation and reference materials
Part 18: Chemical characterization of medical device materials within a risk management
process
Part 19: Physico-chemical, morphological and topographical characterization of material
Pitakthai Chamtim
Academic service unit, GLP testing facility, National Laboratory Animal Center (NLAC), Thailand
30th September 2022 55
58. 58
Biological evaluation of medical devices: Medical gloves
Ref: āļāļēāļĢāļ§āļąāļāđāļĨāļ°āļāļēāļĢāļāļāļŠāļāļāđāļāļĢāļāļĩāļāđāļāļāļļāļāļĄāļ·āļāđāļāļāļĒāđ āđāļāļ·āđāļāļāđāļāļāļāļąāļāļāļēāļĢāđāļāđāđāļāļĢāļāļĩāļ â SiamGlove
63. 63
Biological evaluation of medical devices: Plastic container
ïķ In this report, a specific strategy (solvents, incubation conditions,
and compound identification and quantification protocols) was
developed to generate extractables information from SU
bioprocess bags for use in bio-pharmaceutical manufacturing.
Method
66. Biological evaluation of medical devices: Toothpaste
66
Atomic Absorption Spectrometer (AAS) Inductively couple plasma (ICP)
67. Biological evaluation of medical devices: Toothpaste
67
ïķ Parabens (āļāļēāļĢāļēāđāļāļāļŠāđ)
ï Parabens are used in combination with other types of
preservatives to make synergetic effects against a broad
range of microorganisms.
ï There are concerns on the carcinogenic and allergenic risks
from using paraben-containing products.
ï Parabens are certified by the Ministry of Health. It is safe
when put into various products according to the specified
amount is not more than 0.25%.
Method
69. Biological evaluation of medical devices: Drug eluent stent
69
Paclitaxel Coated Stent
ï§ Paclitaxel (PCL) is an anticancer drug which helps to
prevent restenosis (reblocking) in the artery after stenting.
Ref: Modelling chemistry and biology after implantation of a drug-eluting stent. Part â : Drug transport (aimspress.com)
Drug eluent stent
Method
71. The International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for
Human Use (ICH) guideline
Present by
Pitakthai Chamtim
Academic service unit, GLP testing facility, National Laboratory Animal Center (NLAC), Thailand
28th September 2022
71
75. 75
The International Council for Harmonization of
Technical Requirements for Pharmaceuticals for Human Use
International council harmonization (ICH) āļŠāļ āļēāļĢāļ°āļŦāļ§āđāļēāļāļāļĢāļ°āđāļāļĻāđāļāļ·āđāļāļāļēāļĢāļāļĢāļ°āļŠāļēāļāļāļąāļāļāļāļāļāđāļāļāļēāļŦāļāļāļāļēāļāđāļāļāļāļīāļāļŠāļēāļŦāļĢāļąāļ
āļĒāļēāļŠāļēāļŦāļĢāļąāļāđāļāđāđāļāļĄāļāļļāļĐāļĒāđ ( āđāļāļāļĩ ) āđāļāđāļāļāļ§āļēāļĄāļāļīāļāļĢāļīāđāļĢāļīāđāļĄāļāļĩāđāļĢāļ§āļāļĢāļ§āļĄāļŦāļāđāļ§āļĒāļāļēāļāļāļēāļāļąāļāļāļđāđāļĨāļāļļāļāļŠāļēāļŦāļāļĢāļĢāļĄāļĒāļēāđāļāļ·āđāļāļŦāļēāļĢāļ·āļāđāļāļĩāđāļĒāļ§āļāļąāļāļ āđāļēāļ
āļ§āļīāļāļĒāļēāļĻāļēāļŠāļāļĢāđāđāļĨāļ°āđāļāļāļāļīāļāļāļāļāļāļēāļĢāļāļąāļāļāļēāļāļĨāļīāļāļ āļąāļāļāđāļāļēāļāđāļ āļŠāļąāļāļāļĢāļĢāļĄāđāļĨāļ°āļāļēāļĢāļĨāļāļāļ°āđāļāļĩāļĒāļ
76. Work trial presentation
July â September 2022
Pitakthai Chamtim
Academic service unit, GLP testing facility
National Laboratory Animal Center (NLAC), Thailand
30th September 2022
76
77. 77
OECD-GLP and SOPs
Introduction OECD Principles of GLP series No. 1
âĒ Organization for Economic Co-operation and Development (OECD) is to promote policies that will improve the economic and social well-
being of people around the world (34 Member countries).
âĒ Good Laboratory Practice (GLP) is a quality system concerned with the organizational process and the conditions under which non-clinical
health and environmental safety studies are planned, performed, monitored, recorded, archived and report.
â Apparatus, Material, and Reagents
âĒ should be suitably located and of appropriate design and adequate capacity; should be periodic inspected, cleaned, maintained,
and calibrated according to Standard Operating Procedures study and should not interfere adversely with the test systems
â Test system
âĒ Physical/Chemical
â Test and reference items
âĒ Receipt, Handling, Sampling and Storage
â Characterization
â Standard Operating Procedures
âĒ Receiving of Test item (SOP-G.RA-016), Test item management (SOP-G.RA-017), Preparation of test item (SOP-G.RA-018), Using of
Test Item Custodian Room (SOP-G.RA-062)
78. 78
On study (Mini room) and custodian/preparation (Custodian room)
Non-GLP2022-14: Skin sensitization test of Cellulose hydrogel wound dressing patch in Dunkin Hartley Guinea Pig
â Wound dressing with PVA/CMC with HA
â management of test items includes receiving, storage, and preparation
GLP2022-21: Sub-chronic Oral Toxicity Testing of Centell-S in Wistar Rats
â prepared the sterile water for mixing with test items
Non-GLP2022-22: Skin sensitization test of Cellulose hydrogel wound dressing patch in Dunkin Hartley Guinea Pig
â management of test items includes receiving, storage, and preparation
Receiving test items
from Sponsor and
Storage TI and
record documents
- Microbiological test
- Test item received form
- List of test item
Preparation TI in Custodian
room and record document
- Log book of test item
- Request of test item form
Preparation TI in
Mini room
79. 79
Biological evaluation of medical devices (ISO-10993)
ISO-10993 -6: Tests for local effects after implantation
âĒ ISO-10993 -6 offers general guidelines for evaluating local tissue responses to implants
âĒ Tests for local effects after implantation, Degradable materials, Implant sites and methods for evaluation
ISO-10993 -10: Tests for skin sensitization
âĒ A variety of methods are available for the prospective identification of skin sensitizing chemicals: Buehler test,
Guinea pig maximization test(GPMT), Local lymph node assay(LLNA).
ISO-10993 -11: Tests for systemic toxicity
âĒ This document specifies requirements and gives guidance on procedures to be followed in the evaluation of
the potential for medical device materials to cause adverse systemic reactions; Acute, Subacute, Subchronic
and Chronic toxicity test.
80. 80
Nonclinical vehicles use in animal studies
ïķ Formulation vehicles includes a vehicle, excipients and a container/container components.
ïķ The ideal properties of the vehicle include pharmacologically inert, non-toxic, physically and chemically inert and does not interfere
with therapeutic effect of the active pharmaceutical ingredient (API).
ïķ Injections are prepared by dissolving, solubilising or suspending the active ingredient in a suitable vehicle.
âĒ Aqueous vehicles: Sterile water, Sodium Chloride (NaCl) or water saline
âĒ Non-aqueous: Corn oil, Sesame oil
âĒ Suspending/emulsifying agents: 1% Carboxymethylcellulose (CMC)
ïķ Sterile water is commonly used for dissolving polar substances. None of adverse effects and suitable
for several administration routes.
ïķ Oil is used for dissolving non polar substances. Corn oil is well tolerated in short-term studies ( âĪ1 month),
but which causes altered body weight gain, survival and tumor incidence when administered chronically in rats.
ïķ 1% CMC offer the advantages of low toxicity, poor bioavailability and the ability to create uniform
suspensions or emulsions in relatively low percentage formulations, but may have laxative effect are large dose.
ïķ Water saline is suitable for intravenous, intraperitoneal and subcutaneous administration.
81. 81
Biological evaluation of medical devices (ISO-10993)
ISO-10993 -12: Sample preparation and reference materials
âĒ Preparation of samples and the selection of reference materials for medical devices testing in biological systems
âĒ Test material selection, selection of representative portions from a device, Test sample preparation, selection of and
requirements for reference materials and preparation of extracts.
ISO-10993 -18: Chemical characterization of medical device materials within a risk management process
âĒ Process for characterizing a device (or material) and identification of its materials of construction
âĒ Characterization of the material composition (i.e., chemical constituents) and reporting constituent information to
support assessment of the potential for patient risk in clinical use
ISO-10993 -19: Physico-chemical, morphological and topographical characterization of material
âĒ Compilation of parameters and test methods for the identification and evaluation of the physical, i.e.
physico-chemical, morphological and topographical (PMT) properties of materials in finished medical devices.
85. 85
Biological evaluation of medical devices: Toothpaste
ïķ Parabens (āļāļēāļĢāļēāđāļāļāļŠāđ)
ï Parabens are used in combination with other types of preservatives to make
synergetic effects against a broad range of microorganisms.
ï There are concerns on the carcinogenic and allergenic risks from using paraben-
containing products.
ï Parabens are certified by the Ministry of Health. It is safe when put into various
products according to the specified amount is not more than 0.25%.
86. 86
Biological evaluation of medical devices: Drug-eluent Stent
Paclitaxel Coated Stent
ï§ Paclitaxel (PCL) is an anticancer drug
which helps to prevent restenosis
(reblocking) in the artery after stenting.